The reference sheet: what we take, and how much
Companion to the narrative account. This is the list — what we run, at what dose, how often, and the reasoning where the reasoning is not obvious.
Everything here is a first-hand account of our own protocol. It is not a recommendation, and nothing on this page is prescriptive.
Peptides
| Compound | Who | Frequency |
|---|---|---|
| SuperRUSH | Me | Daily |
| SuperKLOW | Both of us | Daily |
| SuperHEAL | Me | As needed |
SuperKLOW is the one I would point at. My wife had ongoing knee pain and joint problems. Those resolved almost immediately after she started it — fast enough that neither of us had to wonder whether it was working. She has stayed on it daily since.
SuperRUSH is the daily mitochondrial shot, and the 5-Amino-1MQ in it is the single non-GLP-1 compound I would single out for effect. What I have observed personally: consistent daily energy, and — the effect I did not expect — my digestion stays regular. That matters more than it sounds on a GLP-1 protocol, since slowed gastric emptying is part of how these drugs work and constipation is among the most common complaints. I do not get it. I have no literature attributing motility effects to this compound, so I am reporting it as an observation rather than a documented mechanism. It also appears to be part of why I stall less often than the pattern I see in other people.
Both of us run replacement
- Me: testosterone cypionate ~250 mg weekly total, plus hCG — both injected daily, in small subcutaneous doses.
- Her: ~24.4 mg testosterone and ~1 mg estradiol per week, once weekly. She is perimenopausal.
Why I inject daily rather than weekly
Same total milligrams. Completely different hormonal week. A single weekly injection of a long-ester testosterone produces a peak within a day or two and a steady decline after — a peak-to-trough ratio that can approach 3:1 across the week. Dividing the same weekly total into seven small subcutaneous doses produces what the pharmacology literature describes as the flattest achievable curve, with day-to-day levels nearly identical.
The reason that matters is estradiol. Aromatase activity is substrate-driven — large peaks supply more testosterone for conversion, which elevates estradiol more sharply. Smaller, more frequent doses never present the enzyme with a bolus to work on. A retrospective analysis found men switching from weekly to merely twice-weekly injections averaged a 25% reduction in estradiol, with no change in total dose and nothing added. Going to daily takes that further, and for many men it removes the need for an aromatase inhibitor entirely — which avoids the joint pain, crashed estrogen and lipid disruption that come with AI use.
Research published in the Journal of the Endocrine Society has also reported that daily subcutaneous testosterone cypionate produces stable serum levels with less hematocrit elevation than less frequent dosing — the other common reason TRT protocols run into trouble.
A 10,000 IU vial reconstituted with 3 mL, dosed at 20 units on an insulin syringe — roughly 665 IU. That was twice weekly. It is now split across all seven days at the same weekly total, which works out around 190–200 IU a day, and it is mixed into SuperRUSH so it is not a separate shot at all.
The reasoning is the same as for testosterone: small and steady rather than pulsed. Daily microdosing in this range is described in the literature as mimicking endogenous LH pulsatility far better than a weekly bolus. Folding it into a shot I was already taking is what makes it sustainable — two injections became zero additional injections, because the chemistry allowed it.
Seven small injections instead of one sounds worse until you consider that the alternative for most men is one injection plus a daily aromatase inhibitor to clean up after it.
On my dose specifically: 250 mg sits above what is usually described as straight replacement, typically quoted in the 100–200 mg range. Worth saying plainly rather than letting someone else point it out — and it is part of why the lean mass effect has been visible without any training. At true replacement doses the body composition effect is real but modest; higher up the curve it is more pronounced, which is what the dose-response data predicts.
This matters more in the context of aggressive fat loss than most people realise. Obesity and metabolic disease are frequently associated with reduced circulating testosterone, which the literature describes as creating a subset of patients with diminished anabolic reserve going into weight loss — exactly the people who then lose the most lean tissue.
Built around what a deficit actually depletes
We both run a full daily vitamin and mineral stack. Not a token multivitamin — a deliberate list built around what a sustained deficit and a GLP-1 protocol actually deplete. The ones doing the most work:
- Magnesium glycinate — cramps, poor sleep and fatigue on GLP-1s are frequently magnesium deficiency rather than the medication.
- Potassium — depletion is near-universal on reduced food volume, and it drives cramps, fatigue and palpitations.
- Vitamin D3 + K2 — fat tissue sequesters D3, so requirements run higher during and after obesity.
- Collagen and vitamin C together — vitamin C is required for collagen synthesis; either alone is wasted.
- Omega-3 — anti-inflammatory, and research describes EPA/DHA as supporting satiety and muscle protein synthesis.
- A multivitamin appropriate to sex and age — the iron question alone makes this non-interchangeable.
We dropped it, and I want to explain why rather than leave the inconsistency sitting there. It is inconvenient to take daily, it is not cheap, and it made no difference we could detect. But there is a better reason than any of those: we do not train.
Creatine works by increasing phosphocreatine availability for high-intensity effort — which lets you train harder, which builds muscle. Take away the training and you have removed the mechanism. A systematic review and meta-analysis of randomised trials found creatine combined with resistance training increased lean body mass by about 1.1 kg regardless of age, and stated the other half directly: creatine supplementation alone, with no exercise training intervention, was ineffective for lean body mass gains.
Creatine is one of the most studied and safest supplements available, and if you lift, take it. We do not lift. Taking it anyway would have been paying for a mechanism we were not using — which is exactly the kind of thing this whole site exists to argue against.
The two I would not run without
Potassium citrate — both of us, by prescription. This is the one I would tell everyone doing aggressive fat loss to ask their doctor about. Rapid weight loss dramatically increases uric acid excretion, the same mechanism behind gout flares. Citrate alkalinises urine to roughly pH 6.5–7.0, which the literature describes as preventing both uric acid and calcium oxalate stone formation.
I know exactly what happens without it. It is why I was hospitalised twice on keto. Nine months of losing weight faster than I ever did on keto, and not one stone.
Allopurinol runs alongside it. The two do different jobs: potassium citrate alkalinises urine to prevent stones forming, while allopurinol reduces uric acid production upstream. Given that keto put me in hospital twice on exactly this mechanism, I have never been interested in finding out whether one of them alone would have been enough.
One shot a day. Two a week.
Hers is the cleanest demonstration of the whole argument, because it is the shortest. She runs the same 60/30 retatrutide-to-tirzepatide split I do. Estradiol and testosterone are compounded together into a single vial — not two injections, one. Both are cypionate esters and both dissolve in the same oil vehicle, so nothing has to be forced into solution.
The GLP-1 stays on its own, and that is deliberate: GLP-1 agonists do not share a vial with anything, ever. SuperKLOW is separate too, partly the daily schedule and partly what is in it, since copper-containing peptides do not share a vial either.
She takes one a day and two a week — and one of those two is carrying what would otherwise be a pair of separate hormone injections. Where the chemistry allows combining, we combine. Where it says no, they stay separate and we say so.